Rhythm Q1 product revenue $60.1M; IMCIVREE HO launch >150 start forms; net loss $(0.83)/share

RHYTHM PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$0.83 revenue$60,112,000

Q1 2026 net product revenue $60.1M (up 5% sequentially); U.S. revenue $36.9M, ex-U.S. $23.2M.
IMCIVREE received FDA approval for acquired hypothalamic obesity on Mar 19; >150 patient start forms in first six weeks.
European Commission granted marketing authorization for IMCIVREE in acquired HO on May 1, 2026.
Net loss $(56.7)M ($(0.83)/share) vs $(50.8)M ($(0.81)/share) in Q1 2025; cash $340.6M.
Phase 3 EMANATE trial missed primary endpoint; positive post-hoc signals in SRC1 and POMC insufficiencies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

RHYTHM PHARMACEUTICALS, INC. reported first quarter ended March 31, 2026 results: revenue $60.1 million.

Period: first quarter ended March 31, 2026
Revenue: $60.1 million
Result: reported results

Exact text from the filing

Revenue from global sales of IMCIVREE was $60.1 million for the first quarter of 2026

View on SEC.gov

Browse all earnings releases →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-030136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.